185 related articles for article (PubMed ID: 37097530)
1. Therapeutic strategies and clinical evolution of patients with infantile fibrosarcoma: a unique paediatric case series.
Corral Sánchez MD; Jiménez Carrascoso R; Rubio Aparicio P; Plaza López de Sabando D; Sastre Urgelles A; Pozo-Kreilinger JJ; López Gutiérrez JC; Gómez Cervantes M; Ortiz Cruz EJ; Pérez-Martínez A
Clin Transl Oncol; 2023 Nov; 25(11):3307-3311. PubMed ID: 37097530
[TBL] [Abstract][Full Text] [Related]
2. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
DuBois SG; Laetsch TW; Federman N; Turpin BK; Albert CM; Nagasubramanian R; Anderson ME; Davis JL; Qamoos HE; Reynolds ME; Cruickshank S; Cox MC; Hawkins DS; Mascarenhas L; Pappo AS
Cancer; 2018 Nov; 124(21):4241-4247. PubMed ID: 30204247
[TBL] [Abstract][Full Text] [Related]
3. Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.
Bielack SS; Cox MC; Nathrath M; Apel K; Blattmann C; Holl T; Jenewein R; Klenk U; Klothaki P; Müller-Abt P; Ortega-Lawerenz S; Reynolds M; Scheer M; Simon-Klingenstein K; Stegmaier S; Tupper R; Vokuhl C; von Kalle T
Ann Oncol; 2019 Nov; 30 Suppl 8():viii31-viii35. PubMed ID: 32223937
[TBL] [Abstract][Full Text] [Related]
4. Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.
Bielack SS; Cox MC; Nathrath M; Apel K; Blattmann C; Holl T; Jenewein R; Klenk U; Klothaki P; Müller-Abt P; Ortega-Lawerenz S; Reynolds M; Scheer M; Simon-Klingenstein K; Stegmaier S; Tupper R; Vokuhl C; von Kalle T
Ann Oncol; 2019 Nov; 30(Suppl_8):viii31-viii35. PubMed ID: 31738425
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors.
Kang J; Park JW; Won JK; Bae JM; Koh J; Yim J; Yun H; Kim SK; Choi JY; Kang HJ; Kim WS; Shin JH; Park SH
Diagn Pathol; 2020 Sep; 15(1):114. PubMed ID: 32957984
[TBL] [Abstract][Full Text] [Related]
6. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
7. Treatment of infantile fibrosarcoma associated to an abdominal aortic aneurysm with larotrectinib: a case report.
Corral Sánchez MD; Galán Gómez V; Sastre Urgelles A; Plaza López de Sabando D; Rubio Aparicio P; Martínez Martínez L; Alonso Gamarra E; Pozo Kreilinger JJ; Regojo Zapata RM; López Gutiérrez JC; Antolín Alvarado E; Gómez Martín F; Sánchez Torres AM; Marín Manzano E; González Del Valle L; Pérez-Martínez A
Pediatr Hematol Oncol; 2021 Aug; 38(5):504-509. PubMed ID: 33622165
[TBL] [Abstract][Full Text] [Related]
8. A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib.
Caldwell KJ; De La Cuesta E; Morin C; Pappo A; Helmig S
Pediatr Blood Cancer; 2020 Sep; 67(9):e28330. PubMed ID: 32452122
[TBL] [Abstract][Full Text] [Related]
9. Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience.
Orbach D; Brennan B; De Paoli A; Gallego S; Mudry P; Francotte N; van Noesel M; Kelsey A; Alaggio R; Ranchère D; De Salvo GL; Casanova M; Bergeron C; Merks JH; Jenney M; Stevens MC; Bisogno G; Ferrari A
Eur J Cancer; 2016 Apr; 57():1-9. PubMed ID: 26849118
[TBL] [Abstract][Full Text] [Related]
10. Limb salvage of an infant with infantile fibrosarcoma using TRK inhibitor larotrectinib.
Sahni S; Rastogi S; Yadav R; Barwad A
Ecancermedicalscience; 2023; 17():1575. PubMed ID: 37533946
[TBL] [Abstract][Full Text] [Related]
11. Infantile NTRK-associated Mesenchymal Tumors.
Davis JL; Lockwood CM; Albert CM; Tsuchiya K; Hawkins DS; Rudzinski ER
Pediatr Dev Pathol; 2018; 21(1):68-78. PubMed ID: 28683589
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
Yang JCH; Brose MS; Castro G; Kim ES; Lassen UN; Leyvraz S; Pappo A; López-Ríos F; Reeves JA; Fellous M; Penault-Llorca F; Rudzinski ER; Tabatabai G; Vassal G; Drilon A; Trent J
BMC Cancer; 2022 Jun; 22(1):625. PubMed ID: 35672677
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversies.
Orbach D; Sparber-Sauer M; Laetsch TW; Minard-Colin V; Bielack SS; Casanova M; Corradini N; Koscielniak E; Scheer M; Hettmer S; Bisogno G; Hawkins DS; Ferrari A
Eur J Cancer; 2020 Sep; 137():183-192. PubMed ID: 32784118
[TBL] [Abstract][Full Text] [Related]
14. Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma.
Kao YC; Fletcher CDM; Alaggio R; Wexler L; Zhang L; Sung YS; Orhan D; Chang WC; Swanson D; Dickson BC; Antonescu CR
Am J Surg Pathol; 2018 Jan; 42(1):28-38. PubMed ID: 28877062
[TBL] [Abstract][Full Text] [Related]
15. Progressive metastatic infantile fibrosarcoma with multiple acquired mutations.
Furtado LV; Kacar M; Mostafavi R; Shi Z; Ruiz R; Koo SC; Santiago T; Segers B; Krasin MJ; Abramson ZR; Shulkin B; Talbot LJ; Pappo A; Gartrell J
Cold Spring Harb Mol Case Stud; 2023 Apr; 9(2):. PubMed ID: 36997313
[TBL] [Abstract][Full Text] [Related]
16. Larotrectinib followed by selitrectinib in a novel
Goh XN; Seng MS; Loh AHP; Gupta A; Chang KTE; Iyer P
J Oncol Pharm Pract; 2021 Mar; 27(2):485-489. PubMed ID: 32693686
[TBL] [Abstract][Full Text] [Related]
17. Myxoid spindle cell sarcoma with ETV6-NTRK3 fusion.
Kyriazoglou A; Dimitriadis E; Mahaira L; Kotsantis J; Kouloulias V; Kontogeorgakos V; Psyrri A; Agrogiannis G
Cancer Genet; 2022 Nov; 268-269():93-96. PubMed ID: 36274330
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics.
Hung YP; Fletcher CDM; Hornick JL
Histopathology; 2018 Oct; 73(4):634-644. PubMed ID: 29863809
[TBL] [Abstract][Full Text] [Related]
19. [Recurrent and metastatic infantile fibrosarcoma: a case report].
Lagree M; Toutain F; Revillon Y; Gaussin G; Marie-Cardine A; Lemoine F; Vannier JP
Arch Pediatr; 2011 Jan; 18(1):28-32. PubMed ID: 21084177
[TBL] [Abstract][Full Text] [Related]
20. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma.
Rubin BP; Chen CJ; Morgan TW; Xiao S; Grier HE; Kozakewich HP; Perez-Atayde AR; Fletcher JA
Am J Pathol; 1998 Nov; 153(5):1451-8. PubMed ID: 9811336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]